2023
Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample
de Havenon A, Zhou L, Yaghi S, Frontera J, Sheth K. Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample. Stroke 2023, 54: e194-e198. PMID: 37021563, PMCID: PMC10121243, DOI: 10.1161/strokeaha.122.041929.Peer-Reviewed Original ResearchConceptsHealth Stroke ScaleStroke ScaleStroke severityLowest quartileCOVID-19Acute ischemic stroke outcomesAcute ischemic stroke severityHigher stroke severityHospital stroke mortalityIschemic stroke outcomeHigher National InstitutesNational Inpatient SampleCross-sectional cohortIschemic stroke severityCOVID-19 statusNational InstituteHospital mortalityAdjusted riskHospital dischargeIschemic strokeStroke outcomeStroke mortalityAIS severityInpatient SampleExposure statusEffect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity
de Havenon A, Abbasi M, Yaghi S, Delic A, Bangad A, Johnston K, Tirschwell D, Sheth K. Effect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity. Annals Of Neurology 2023, 93: 1106-1116. PMID: 36852919, DOI: 10.1002/ana.26621.Peer-Reviewed Original ResearchConceptsIV-tPAHigher NIHSSIschemic strokeAtrial fibrillationNational Inpatient Sample (NIS) 2016Non-Hispanic white raceOlder ageBaseline National InstitutesDEFUSE-3 trialsHealth Stroke ScalePost-stroke mortalityIschemic stroke mortalityEffect of alteplaseRisk of mortalityLogistic regression modelsAnn NeurolFAST-MAGIMS IIISevere ISHospital mortalityIntravenous alteplaseSevere strokeStroke ScaleStroke severityFunctional outcome
2021
Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19
Frontera JA, Melmed K, Fang T, Granger A, Lin J, Yaghi S, Zhou T, Lewis A, Kurz S, Kahn DE, de Havenon A, Huang J, Czeisler BM, Lord A, Meropol SB, Troxel AB, Wisniewski T, Balcer L, Galetta S. Toxic Metabolic Encephalopathy in Hospitalized Patients with COVID-19. Neurocritical Care 2021, 35: 693-706. PMID: 33725290, PMCID: PMC7962078, DOI: 10.1007/s12028-021-01220-5.Peer-Reviewed Original ResearchConceptsHypoxic-ischemic encephalopathyHospital mortalityTime-dependent Cox proportional hazards modelsSequential Organ Failure Assessment scoreSevere acute respiratory syndrome coronavirus 2Organ Failure Assessment scoreAcute respiratory syndrome coronavirus 2Intensive care unit requirementSARS-CoV-2 infectionCOVID-19Cox proportional hazards modelRespiratory syndrome coronavirus 2Longer hospital lengthNew York City hospitalsPrimary neurological diagnosisStructural brain diseaseToxic-metabolic encephalopathyDate of admissionSyndrome coronavirus 2Proportional hazards modelCoronavirus disease 2019Coprimary outcomesHospital deathHospital lengthObservational cohort
2020
A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients in New York City
Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, Snyder T, Berger S, Yang D, Granger A, Morgan N, Patel P, Gutman J, Melmed K, Agarwal S, Bokhari M, Andino A, Valdes E, Omari M, Kvernland A, Lillemoe K, Chou SH, McNett M, Helbok R, Mainali S, Fink EL, Robertson C, Schober M, Suarez JI, Ziai W, Menon D, Friedman D, Friedman D, Holmes M, Huang J, Thawani S, Howard J, Abou-Fayssal N, Krieger P, Lewis A, Lord AS, Zhou T, Kahn DE, Czeisler BM, Torres J, Yaghi S, Ishida K, Scher E, de Havenon A, Placantonakis D, Liu M, Wisniewski T, Troxel AB, Balcer L, Galetta S. A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients in New York City. Neurology 2020, 96: 10.1212/wnl.0000000000010979. PMID: 33020166, PMCID: PMC7905791, DOI: 10.1212/wnl.0000000000010979.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBrain DiseasesCOVID-19FemaleHospital MortalityHospitalizationHumansIntubation, IntratrachealMaleMiddle AgedNervous System DiseasesNeurotoxicity SyndromesNew York CityOrgan Dysfunction ScoresPatient DischargeProspective StudiesSex FactorsSpinal Cord DiseasesYoung AdultConceptsNew neurologic disordersSARS-CoV-2 infectionLikelihood of dischargeNeurologic disordersHospital mortalityHigher Sequential Organ Failure Assessment scoreLaboratory-confirmed SARS-CoV-2 infectionSequential Organ Failure Assessment scoreCOVID-19Severe acute respiratory syndrome coronavirus 2Organ Failure Assessment scoreAcute respiratory syndrome coronavirus 2Hospitalized COVID-19 patientsHypoxic/ischemic injuryCOVID-19 symptom onsetRespiratory syndrome coronavirus 2Meningitis/encephalitisSevere systemic illnessCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019SARS-CoV-2SOFA scoreHospital outcomesHospitalized adultsAnticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System
Kvernland A, Kumar A, Yaghi S, Raz E, Frontera J, Lewis A, Czeisler B, Kahn DE, Zhou T, Ishida K, Torres J, Riina HA, Shapiro M, Nossek E, Nelson PK, Tanweer O, Gordon D, Jain R, Dehkharghani S, Henninger N, de Havenon A, Grory BM, Lord A, Melmed K. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System. Neurocritical Care 2020, 34: 748-759. PMID: 32839867, PMCID: PMC7444897, DOI: 10.1007/s12028-020-01077-0.Peer-Reviewed Original ResearchConceptsHemorrhagic strokeTherapeutic anticoagulationClinical characteristicsThrombotic complicationsHistorical controlsCOVID-19Exact testHigher initial NIHSS scoreSARS-CoV-2 patientsInitial NIHSS scoreRetrospective cohort studyHealthcare systemFischer's exact testCOVID-19 infectionNon-aneurysmal SAHMajor healthcare systemOverall low rateAnticoagulation useEmpiric anticoagulationHospital mortalityNIHSS scoreCohort studyCommon etiologyIntraparenchymal hemorrhageMost hemorrhages